-Osimertinib (TagrissoTM, AZD9291 AstraZeneca, Figure 5a) is an irreversible orally administered, EGFR-specific TKI with strong selectivity to EGFR-activating mutations as well as the secondary T790M resistance mutation in patients with advanced NSCLC (Figure 5a, Table 1) [160]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.